Combinations and Targeted Agents: Better Survival in Mantle Cell Lymphoma
0
/
RSS Feed
Martin Dreyling
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.
MARTIN DREYLING, University Hospital Grosshaden, Munich
Since the 1970s therapies for mantle cell lymphoma have greatly extended life, Martin Dreyling told conference delegates in Paris. He gave Peter Goodwin his latest data on combination therapy using the antibody, rituximab, and the emerging rôles of other targeted agents.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/080226_martin_dreyling.mp3]
Share
